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Pseudomonas aeruginosa causes acute and chronic infections in human. Its increasing
resistance to antibiotics requires alternative treatments that are more effective than
available strategies. Among the alternatives is the unconventional usage of conventional
antibiotics, of which the macrolide antibiotic azithromycin (AZM) provides a paradigmatic
example. AZM therapy is associated with a small but consistent improvement in
respiratory function of cystic fibrosis patients suffering from chronic P. aeruginosa
infection. Besides immunomodulating activities, AZM represses bacterial genes involved
in virulence, quorum sensing, biofilm formation, and motility, all of which are due to
stalling of ribosome and depletion of cellular tRNA pool. However, how P. aeruginosa
responds to and counteracts the effects of AZM remain elusive. Here, we found that
deficiency of PA3297, a gene encoding a DEAH-box helicase, intensified AZM-mediated
bacterial killing, suppression of pyocyanin production and swarming motility, and
hypersusceptibility to hydrogen peroxide. We demonstrated that expression of PA3297
is induced by the interaction between AZM and ribosome. Importantly, mutation of
PA3297 resulted in elevated levels of unprocessed 23S-5S rRNA in the presence of
AZM, which might lead to increased susceptibility to AZM-mediated effects. Our results
revealed one of the bacterial responses in counteracting the detrimental effects of AZM.
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INTRODUCTION
Pseudomonas aeruginosa is a versatile Gram-negative pathogenic bacterium, that can cause various
infections in human (de Bentzmann and Plésiat, 2011; Campa et al., 2012). During infection,
P. aeruginosa produces multiple virulence factors to facilitate colonization (Sadikot et al., 2005;
Kipnis et al., 2006; Hauser, 2009; Liu et al., 2015). Meanwhile, its highly intrinsic antibiotic
resistance and biofilm forming ability greatly hinder the eradication of this pathogen (Høiby
et al., 2005). In patients suffering from cystic fibrosis (CF) and chronic obstructive pulmonary
disease (COPD), P. aeruginosa caused chronic respiratory infections are responsible for most of the
morbidity and mortality (Rabin et al., 2004; Rada and Leto, 2013). Intensive antibiotic treatment
has been used to maintain the lung function and extend lifespan of the patients (Doring et al.,
2000). However, the increasing antibiotic resistance has been compromising clinical efficacy of
traditional antibiotics. Thus, alternatives or unconventional usage of the antibiotics are urgently
needed (Breidenstein et al., 2011; Poole, 2011; Imperi et al., 2014).
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The macrolide antibiotic azithromycin (AZM) provides a
paradigmatic example of an unconventional antibacterial drug
for P. aeruginosa treatment. Although, P. aeruginosa is highly
resistance to macrolides owning to its low outer membrane
permeability and the resistance-nodulation-cell division (RND)
systems, AZM treatment benefits patients suffering from both
intermittent and chronic P. aeruginosa infections (Saiman et al.,
2003; Lister et al., 2009; Blasi et al., 2010; Steel et al., 2012;
Aminov, 2013; Morita et al., 2013). AZM has been shown to have
immunomodulatory activity, which attenuates the inflammatory
response and promotes macrophage phagocytic activity (Legssyer
et al., 2006; Steinkamp et al., 2008; Tsai et al., 2009). Furthermore,
AZM exhibits bactericidal effect on stationary growth phase
P. aeruginosa cells (Lovmar et al., 2004, 2009; Imamura et al.,
2005; Köhler et al., 2007; Starosta et al., 2010; Gödeke et al., 2013).
And sub-inhibitory concentrations of AZM suppress biofilm
formation, motility, and production of multiple virulence factors,
including proteases, pyocyanin, exotoxin A, phospholipase C
(PLC), exopolysaccharides, and other quorum-sensing (QS)
regulated genes in P. aeruginosa (Molinari et al., 1992, 1993;
Tateda et al., 2001; Favre-Bonté et al., 2003; Gillis and Iglewski,
2004). The AZM-mediated killing of stationary-phase bacterial
cells and reduced expression of QS-regulated virulence factors
require interaction between AZM and ribosome (Köhler et al.,
2007). AZM binds in the nascent peptide exit tunnel (NPET),
resulting in ribosome stalling and depletion of the intracellular
pools of aminoacyl-tRNAs (Lovmar et al., 2004, 2009; Köhler
et al., 2007; Starosta et al., 2010; Gödeke et al., 2013). The
effects of AZM on P. aeruginosa can be counteracted by over
expression of ErmBP or a peptidyl-tRNA hydrolase, which
blocks the interaction between AZM and ribosome by modifying
the 23S rRNA or increases the intracellular aminoacyl-tRNA
level, respectively (Köhler et al., 2007; Gödeke et al., 2013).
However, how P. aeruginosa response to AZM treatment remains
unclear. Understanding the mechanisms that P. aeruginosa
uses to counteract AZM treatment may provide clues to
enhance AZM-mediated virulence inhibitory and bacterial killing
effects.
A large RNA helicase family named DExD/H box helicases
are characterized by a conserved DExD/H box sequence (Cordin
et al., 2006; Linder and Jankowsky, 2011), and play crucial roles
in rRNA processing, translation initiation, and mRNA decay
(Iost et al., 2013; Linder and Fuller-Pace, 2013). In addition,
the DExD/H box helicases have been shown to participate in
bacterial responses to various stresses, such as cold shock, pH,
osmotic, and oxidative stresses (Owttrim, 2013). And several
DEAD family RNA helicases, which belong to a specific subfamily
of DExD/H box helicases, have been shown to regulate virulence
factors in Escherichia coli, Borrelia burgdorferi, Staphylococcus
aureus, Listeria monocytogenes, and P. aeruginosa (Koo et al.,
2004; Salman-Dilgimen et al., 2011, 2013; Oun et al., 2013;
Bareclev et al., 2014; Intile et al., 2015). The pleiotropic
functions of DExD/H box family RNA helicases intrigued us to
suspect that they might be involved in the bacterial response
to AZM treatment. In this study, we found that deficiency
in a DEAH box helicase, PA3297, renders P. aeruginosa more
susceptible to the killing and virulence suppression by AZM. Our
results suggest that the expression of PA3297 was up regulated
in the presence of AZM, which might promote 23S rRNA
maturation to counteract the inhibitory effect of AZM on protein
elongation.
MATERIALS AND METHODS
Strains and Plasmids
The bacterial strains and plasmids used in this study are
listed in Table 1 (Simon et al., 1983; Hoang et al., 1998;
Choi and Schweizer, 2006; Liberati et al., 2006). The E. coli
strains DH5α, S17-1 and P. aeruginosa strains were routinely
cultured in Luria-Bertani (LB) broth at 37◦C. Antibiotics were
used at the following concentrations: for E. coli, ampicillin
100 µg/ml, tetracycline 10 µg/ml, and gentamicin 10 µg/ml; for
P. aeruginosa, carbenicillin 150µg/ml, tetracycline 50µg/ml, and
gentamicin 50 µg/ml.
DNA Methods
DNA manipulations were performed according to standard
protocols or following manufacturers’ instructions (Hoang et al.,
1998; Zheng et al., 2004; Choi and Schweizer, 2006). The
pEX18Tc::1PA3297 (pTH1501) was constructed by cloning the
1002-bp upstream and 964-bp downstream fragments of PA3297
coding region into the KpnI-HindIII sites of plasmid pEX18Tc.
The fragments were amplified from the PA14 chromosome
with primers PA14-UPA3297-FF, PA14-UPA3297-FR, PA14-
DPA3297-FF, and PA14-DPA3297-FR (Table 2), respectively.
Deletion of the PA3297 gene was confirmed by PCR with
primers PA14-PA3297-FF and PA14-PA3297-FR (Table 2). For
the complementation of PA3297, the PA3297 gene was amplified
from the PA14 chromosome by PCR with the primers PA14-
PA3297-FF and PA14-PA3297-FR (Table 2). The PCR product
was ligated into the EcoRI- SacI sites of pUC18t-mini-Tn7T-
Gm, resulting in pTH1502. The plasmid was introduced into
the 1PA3297 mutant by electroporation, along with the helper
plasmid pTNS3 (Choi and Schweizer, 2006). Insertion of
the PA3297 gene into the chromosome was confirmed by
PCR with primers PTn7R and PglmS−down (Table 2; Choi and
Schweizer, 2006). The site-directed mutagenesis was performed
as previously described (Zheng et al., 2004). The mutation sites
were chosen based on the conserved critical residues of other
bacterial DExD-box proteins (Koo et al., 2004; Cordin et al.,
2006). Briefly, PCR amplification was performed with pTH1502
as template and with primers listed in Table 2, for K101A,
D192A, and SAT224-226AAA mutations, respectively. The PCR
products were treated by DpnI for 3 h at 37◦C and purified before
transformation. The correctly mutated clones were identified by
DNA sequencing.
Assay for Pyocyanin Production
The pyocyanin concentration was determined as described
previously (Essar et al., 1990). Briefly, 1 ml supernatant from
each 24-h-old bacteria culture grown in the absence or presence
of AZM was extracted with 0.5 ml of chloroform. Then, 0.4 ml
solution from the lower organic phase was re-extracted into
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TABLE 1 | Bacterial strains and plasmids used in this study.
Strain or plasmid Descriptiona Reference or origin
E. coli strains
DH5α F−, ϕ80dlacZ1M15,1(lacZYA-argF)U169, deoR, recA1, endA1, hsdR17(rk−,mk+), phoA,
supE44, λ−, thi1, gyrA96, relA1
TransGen
S17-1 thi pro hsdR recA Tra+ Simon et al., 1983
P. aeruginosa strains
PA14 Wild type Pseudomonas aeruginosa strain PA14 Liberati et al., 2006
PA0426::Tn PA14 with a transposon inserted at PA0426 Liberati et al., 2006
PA0455::Tn PA14 with a transposon inserted at PA0455 Liberati et al., 2006
PA2840::Tn PA14 with a transposon inserted at PA2840 Liberati et al., 2006
PA3002::Tn PA14 with a transposon inserted at PA3002 Liberati et al., 2006
PA3272::Tn PA14 with a transposon inserted at PA3272 Liberati et al., 2006
PA3297::Tn PA14 with a transposon inserted at PA3297 Liberati et al., 2006
PA3308::Tn PA14 with a transposon inserted at PA3308 Liberati et al., 2006
PA3861::Tn PA14 with a transposon inserted at PA3861 Liberati et al., 2006
PA3950::Tn PA14 with a transposon inserted at PA3950 Liberati et al., 2006
1PA3297 PA14 with PA3297 in frame deletion This study
1PA3297/att7::PA3297 PA14 1PA3297 with insertion of a single copy of PA3297 driven by its own promoter at attTn7
sites
This study
1PA3297/att7::PA3297 K101A PA14 1PA3297 complemented with a single copy of PA3297 acquired a lysine101 mutation to
alanine
This study
1PA3297/att7::PA3297 D192A PA14 1PA3297 complemented with a single copy of PA3297 acquired an aspartate192
mutation to alanine
This study
1PA3297/att7::PA3297SAT224AAA PA14 1PA3297 complemented with a single copy of PA3297 acquired a serine224 and
threonine226 mutation to alanines
This study
Plasmids
pEX18Tc Broad-host-range gene replacement vector; sacB TETr Hoang et al., 1998
pUC18t-mini-Tn7T-Gm For gene insertion in chromosome; GENr Choi and Schweizer, 2006
pTNS3 Helper plasmid Choi and Schweizer, 2006
pFLP2 Source of Flp recombinase; sacB, AMPr/CARr Hoang et al., 1998
pTH1501 pEX18Tc::1PA3297; TETr This study
pTH1502 PA3297 gene of PA14 on pUC18T-Mini-Tn7T-Gm with its own promoter; GENr This study
aAMPr, ampicillin resistant; TETr, tetracycline resistant; GENr, gentamicin resistance; CARr, carbenicillin resistant.
0.3 ml of 0.2 N HCl to give a pink solution, whose absorbance was
measured at 520 nm. Concentrations of pyocyanin (mg/ml) were
calculated by multiplying the OD520 by 32.01 (Kurachi, 1958).
Antibiotic Susceptibility Assay
Minimum inhibitory concentrations (MICs) of P. aeruginosa to
antimicrobial agents were determined by serial twofold broth
dilution in LB medium, as described previously (Jo et al., 2003).
MICs were recorded as the lowest concentration of antibiotic
inhibiting visible growth after 24 h of incubation at 37◦C.
Stationary-Phase Bacterial Cell Killing
Assay
The killing assay was performed as described previously (Köhler
et al., 2007). Briefly, bacteria were inoculated in LB medium
and grown for 16 h at 37◦C. The culture of each strain was
diluted to an OD600 of 0.05 and cultured at 37◦C. After reaching
stationary phase (OD600, 3.0), indicated concentrations of AZM
were added to the 2-ml aliquots of the cultures. Then the bacteria
were cultured for 20–22 h at 37◦C. The viable bacterial numbers
were determined by serial dilution and plating on drug-free LB
agar plates. The survival rate of each strain was calculated as live
bacterial number in AZM treated sample divided by the bacterial
number of the corresponding untreated sample.
Biofilm Tolerance to AZM
The biofilm resistance was measured as previously described with
minor modifications (Bjerkan et al., 2009; Billings et al., 2013;
Liao et al., 2013). Briefly, overnight bacterial cultures were diluted
to an OD600 of 0.025. 150 µl of the bacteria were incubated in
each well of a 96-well plate at 37◦C without agitation (Brencic
et al., 2009). After 24 h, the planktonic bacteria were discarded
by aspiration. Then, the biofilms were treated with 150 µl LB
medium containing indicated concentrations of AZM for 2 h.
The medium in each well was replaced with fresh LB medium,
and subjected to sonication at a frequency of 40 kHz, with a
power output of 300 W, at 37◦C for 5 min. The live bacteria were
enumerated by serial dilution and plating.
Growth Assay
Overnight culture of each strain was diluted into fresh LB (150µl)
to an OD600 of 0.05 in each well of a 96-well plate without or
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TABLE 2 | Primers used in this study.
Primersa Nucleotide sequence (5′→3′)b
Cloning of upstream and downstream fragments for PA3297 deletion
PA14-UPA3297-FF GAAAGCGGTACCGAAGTAAGTCCGCCGTTGCC (Kpn I)
PA14-UPA3297-FR CAGCTTTCTAGAGGTGCTGTCGTCGCTCTGGT (Xba I)
PA14-DPA3297-FF TTGCAGTCTAGACGCTGGATGCTGGAGGAGTA (Xba I)
PA14-DPA3297-FR CGCCGGAAGCTTCACCGAGCAGTGGCTGAAGAC
(Hind III)
Cloning of gene PA3297 for complementation
PA14-PA3297-FF TGAAGAGAATTCGCCAGAAGTAAGTCCGCCGTTGCC
(EcoR I)
PA14-PA3297-FR CACCGGGAGCTCCGACCAGACCGACCTGTTCTTCA
CCAT (Sac I)
PTn7R CACAGCATAACTGGACTGATTTC
PglmS−down GCACATCGGCGACGTGCTCTC
Primers used for site-directed mutagenesis of PA3297
PA3297-K101A-FF GCGAGACCGGCTCGGGC . . . . .GCGACCACCCAG
PA3297-K101A-FR T. . . . .CGCGCCCGAGCCGGTCTCGCCGGCGATC
PA3297-D192A -FF TACGACACGCTGATCGTC. . . . .GCCGAAGCCCAC
PA3297-D192A -FR C . . . . .GGCGACGATCAGCGTGTCGTAGCGCTCCAG
PA3297-SAT224-
226AAA-FF
GCTGATCATCACC. . . . .GCGGCG . . . . .GCCATCGACCTGGAG
PA3297-SAT224-
226AAA-FR
T. . . . . .GGCCGC . . . . .CGCGGTGATGATCAGCTTCAGGTCC
RT-qPCR primers for gene expression measurements
23S-R-FF AAAGATAACCGCTGAAAG
23S-R-FR CTATCAACGTCGTAGTCT
5S-R-FF CGAACTCAGAAGTGAAAC
5S-R-FR CTTGACGATGACCTACTC
23S-5S-R -FF GTACTAATTGCCCGTGAG
23S-5S -R-FR GTTCCAACGCTCTATGAT
aThe direction of the primer is indicated at the end of the primer designation as
follows: FF for forward and FR for reverse. bThe solid underlines are the sites of
listed restriction enzymes; the dotted underlines are the sites for mutagenesis, with
all the residues changed into alanine.
with different concentrations of AZM. The plate was incubated
at 37◦C with constant agitation (Lau et al., 2012; Guénard et al.,
2014). The bacterial growth was monitored by measuring the
OD600 every 30 min for 12 h by a Varioskan Flash microplate
reader (Thermo Electron Corporation).
H2O2 Susceptibility Assay
Overnight cultures of the P. aeruginosa strains were diluted to an
OD600 of 0.05 and cultured at 37◦C. When the OD600 reached
0.3 (about 1.5–2 h later), AZM (0.5 µg/ml) was added if needed.
When the OD600 reached 2.0 (about 3 h later), bacteria from
500 µl culture were collected and washed twice with phosphate
buffered saline (PBS). Then the bacteria were resuspended in
PBS with or without 10% H2O2 and incubated for 15 min. The
live bacterial numbers were determined by serial dilution and
plating.
Motility Assay
The swarming motility was tested on modified M9 medium
plates supplemented with 0.2% glucose, 1 mM MgSO4, and
0.05% glutamate as the nitrogen source. 0.5% agar was used
for solidification. Two microliters of exponential growth phase
P. aeruginosa was deposited on the plates, then incubated for 18 h
at 37◦C (Köhler et al., 2007).
Total RNA Isolation and Quantitative
Real-Time PCR
Overnight cultures of P. aeruginosa strain PA14 and 1PA3297
were diluted into fresh LB medium to an OD600 of 0.05. The
bacteria were grown at 37◦C with agitation (200 rpm). When
the OD600 reached 0.3 (about 1.5–2 h later), AZM was added to
reach indicated concentrations. Samples were harvested when the
OD600 reached 2.0 (about 3 h later; Skindersoe et al., 2008). Total
RNA was isolated with an RNeasy Minikit (Tiangen Biotech).
The cDNA from each RNA sample was synthesized with reverse
transcriptase and random primers (Takara). Real-time PCR was
performed with SYBR premix Ex Taq (Roche). The conserved
hypothetical protein coding gene PA1769 was used as an internal
control (Son et al., 2007). The primers used in quantitative
real-time PCR were listed in Table 2, with a designation of
“RT-qPCR.”
Statistical Analysis
When indicated, Student’s t-test (two-tailed) was used to
determine whether the deletion of PA3297 resulted in any
significant differences compared to the wild-type cells treated
with the same concentrations of AZM.
RESULTS
Deficiency of PA3297 Intensifies the
Effects of AZM on Pyocyanin Production
As pyocanin production is suppressed by AZM (Molinari
et al., 1992, 1993; Tateda et al., 2001; Favre-Bonté et al., 2003;
Gillis and Iglewski, 2004), which can be easily observed and
quantified, we used this phenotype to test whether DExD/H
box RNA helicases are involved in bacterial response to AZM
treatment. There are 17 DExD/H box RNA helicases in the
genome of P. aeruginosa strain PA14 (www.pseudomonas.com;
Winsor et al., 2011). There are nine DExD/H box helicase
mutants in the non-redundant PA14 transposon mutants library,
however, the other eight DExD/H box helicase mutants are
not available (Table 1; Liberati et al., 2006; Breidenstein et al.,
2011). Thus, we examined pyocyanin production of the available
mutants in the absence and presence of AZM at an OD600
of 2.0. A PA3297::Tn mutant displayed a significant decrease
in pyocyanin production in the presence of AZM, whereas no
difference was observed in the absence of AZM (Figure 1A). To
confirm the role of PA3297, we generated an in frame deletion
of PA3297 in PA14. The wild type PA14 and the 1PA3297
mutant were grown in the absence or presence of 2, 5, or
10 µg/ml AZM. When the bacteria reached same density (OD600
of 2.0), we measured the pyocyanin levels. AZM inhibited the
production of pyocyanin in the wild type strain in a dose
dependent manner. However, the production of pyocyanin by
the mutant was repressed more severely in the presence of AZM
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FIGURE 1 | Mutation of PA3297 intensified the AZM mediated
inhibition of pyocyanin production. (A) Wild type PA14 and the
mutants of DExD/H box helicases were grown to an OD600 of 2.0 in
the absence or presence of 5 µg/ml AZM at 37◦C and the pyocyanin
concentrations were measured. (B) Bacteria of wild type PA14, 1PA3297
mutant and the complementation strain were grown in the absence or
presence of 2, 5, or 10 µg/ml AZM. When the OD600 reached 2.0, the
pyocyanin concentrations were measured. The values are the means of
three replicates and the error bars display the standard deviations. “ND”
standards for “not detected.” ∗p < 0.05 compared to PA14 or the
complemented strain by student’s t-test.
at all the tested concentrations (Figure 1B). Complementation
with a PA3297 gene restored the production of pyocyanin
(Figure 1B).
Increased Killing of the 1PA3297 Mutant
by AZM
Stationary growth phase P. aeruginosa cells are susceptible to
AZM (Lovmar et al., 2004, 2009; Imamura et al., 2005; Köhler
et al., 2007; Starosta et al., 2010; Gödeke et al., 2013). To test
whether mutation of PA3297 renders higher susceptibility, we
performed the stationary-phase cells killing assay as previously
FIGURE 2 | Increased killing of the 1PA3297 mutant by AZM.
(A) AZM-mediated killing of wild type PA14, the 1PA3297 mutant and
the mutant complemented with wild type or the mutated PA3297.
Stationary-phase bacteria were treated with 2, 5, or 10 µg/ml AZM for
20 h at 37◦C. The numbers of live bacteria were determined by serial
dilution and plating. (B) AZM-mediated killing of biofilm. 24-h-old biofilms
formed by wild type PA14, the 1PA3297 mutant and the complemented
strain were treated with 5 µg/ml, 10 µg/ml AZM or not for 2 h.
Bacteria in the biofilm were dissociated from the wells by gentle
sonication. The viable bacteria were determined by serial dilution and
plating. The averages and associated standard deviations from three
replicates are shown. ∗p < 0.05 compared to PA14 or the
complemented strain by student’s t-test.
described (Imamura et al., 2005; Köhler et al., 2007; Gödeke et al.,
2013). Stationary-phase cells of PA14, the 1PA3297 mutant and
the complementation strain were subjected to treatment with
AZM at the concentrations of 2, 5, and 10 µg/ml. As shown in
Figure 2A, the AZM-mediated killing of the 1PA3297 mutant
was significantly increased at all of the AZM concentrations
tested. The most significant difference was observed at the
concentration of 10 µg/ml, where the survival rate of the
mutant was approximately 1% of those of the wild type and
complemented strains. In addition, the 1PA3297 mutant was
more susceptible to another macrolid antibiotic, erythromycin,
with a fourfold lower MIC compared to the wild type strain PA14
(Table 3).
Next, we tested the susceptibility of the 1PA3297 mutant
to lincosamides, whose bactericidal mechanism is similar to
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macrolides (Tenson et al., 2003; Wilson, 2014). Indeed, mutation
in PA3297 increased the bacterial susceptibility to lincomycin
and clindamycin (Table 3). However, no increase of susceptibility
was observed to other antibiotics, including ciprofloxacin,
carbenicillin, meropenem, tetracycline, tobramycin, kanamycin,
chloramphenicol, or polymyxin B (Supplementary Table S1).
These results suggest that PA3297 plays an important role in the
resistance against antibiotics targeting the peptide exit tunnel of
ribosome.
PA3297 is a putative RNA helicase belonging to the DEAH-
box family proteins, which are characterized by the presence
of seven to nine conserved motifs (Tanner and Linder, 2001).
In the E. coli RNA helicases DbpA and HrpA, the conserved
residues GETGSGKT in motifI, DEAH in motifII, and SAT
in motifIII have been shown to be required for interaction
with and hydrolysis of NTP (Koo et al., 2004; Linder and
Fuller-Pace, 2013). To determine whether these critical residues
within motifs I, II, and III are important for PA3297 in
the resistance to macrolides and lincosamides, we altered the
residues by site-directed mutagenesis. Specifically, the K101
in motif I or the D167 in motif II was mutated to alanine.
The S224 and T226 in motif III were both replaced with
alanine. Each mutated PA3297 was transferred into the1PA3297
mutant and the susceptibility to antibiotics was tested. None
of the mutated PA3297 was able to restore the survival rate
of the mutant (Figure 2A). In addition, the mutated PA3297
was unable to restore the resistance of the 1PA3297 mutant
to macrolides, lincomycin, and clindamycin (Table 3). These
results suggest that the RNA helicase function of PA3297
is required for its role in the resistance to macrolides and
lincosamides.
Clinically, AZM has been used in the treatment of chronic
P. aeruginosa infection (Saiman et al., 2003; Blasi et al., 2010),
which is characterized by biofilm formation (Singh et al., 2000).
The biofilm is notorious for high antibiotic tolerance, which
severely hinders eradication of the bacteria (López et al., 2010;
Breidenstein et al., 2011). We suspected that mutation of PA3297
might increase the killing efficacy of AZM on the biofilm.
Indeed, the survival rates of the 1PA3297 mutant in biofilm
were lower than those of the wild type PA14 at various AZM
concentrations, which were restored by complementation with a
wild type PA3297 (Figure 2B).
TABLE 3 | Bacterial susceptibilities to macrolides and lincosamides.
Strain MIC (µg/ml)a
ERY AZM LIN CLI
PA14 300 400 12800 4800
1PA3297 75 100 3200 2400
1PA3297/att7::PA3297 300 400 >12800 9600
1PA3297/att7::PA3297 K101Ab 75 100 6400 1600
1PA3297/att7::PA3297 D192Ab 75 100 3200 2400
1PA3297/att7::PA3297 SAT224AAAb 75 100 6400 2400
aERY, erythromycin; AZM, azithromycin; LIN, lincomycin; CLI, clindamycin.
bMutants with single or triple amino acid changes.
Mutation of PA3297 Increases the
Bacterial Susceptibility to Hydrogen
Peroxide in the Presence of AZM
It has been shown that AZM treatment impairs the oxidative
stress response in P. aeruginosa (Nalca et al., 2006), which
intrigued us to test whether mutation of PA3297 leads to further
impairment. The H2O2 susceptibility assay was performed in the
presence of 0.5µg/ml AZM, as the growth rates of wild type PA14
and the 1PA3297 mutant were similar at this concentration of
AZM (Supplementary Figure S1). The wild type PA14, 1PA3297
mutant and the complemented strain were grown without or
with AZM to an OD600 of 2.0, and then treated with 10% H2O2
for 15 min. In the presence of AZM, the 1PA3297 mutant was
more susceptible to H2O2 than the wild type and complemented
strains, whereas no difference was observed in the absence of
AZM (Figure 3). These results suggest that PA3297 is involved
in the bacterial oxidative stress response in the presence of AZM.
Mutation of PA3297 Intensifies the Inhibitory
Effect of AZM on Swarming Motility
Besides oxidative stress response, AZM suppresses swarming
motility (Tateda et al., 2001; Köhler et al., 2007; Gödeke et al.,
2013). Same numbers of wild type PA14 and the1PA3297 mutant
were inoculated on the plates containing various concentrations
of AZM. As shown in Figure 4, 10 µg/ml AZM suppressed
the swarming motility of wild type PA14 obviously, whereas
the lower concentrations of AZM showed no inhibitory effect.
However, starting from 2 µg/ml, AZM suppressed the swarming
motility of the 1PA3297 mutant in a dose dependent manner.
Complementation with a PA3297 gene restored the swarming
motility in the presence of AZM (Figure 4).
FIGURE 3 | Hydrogen peroxide (H2O2) mediated killing of bacteria.
PA14, the 1PA3297 mutant and complemented strain were grown at 37◦C in
the absence or presence of 0.5 µg/ml AZM to an OD600 of 2.0. Bacteria were
collected and washed with PBS. Then the bacteria were incubated in PBS
with or without 10% H2O2 for 15 min. The live bacterial numbers were
determined by serial dilution and plating. ∗p < 0.05 compared to PA14 or the
complemented strain by student’s t-test.
Frontiers in Microbiology | www.frontiersin.org 6 March 2016 | Volume 7 | Article 317
fmicb-07-00317 March 14, 2016 Time: 17:47 # 7
Tan et al. Role of PA3297 in Bacterial Response to Azithromycin
FIGURE 4 | Bacterial swarming motility. PA14 (i), the 1PA3297 mutant (ii)
and the complemented strain (iii) were inoculated on plates containing
indicated concentrations of AZM.
Interaction between AZM and Ribosome
Induces the Expression of PA3297
Our results so far suggested that PA3297 is involved in the
bacterial response to AZM treatment. To test whether the
expression of PA3297 is induced by AZM treatment, wild type
PA14 was grown in the absence or presence of AZM at various
concentrations and the relative RNA levels of PA3297 were
determined by real time PCR. Indeed, the expression of PA3297
was induced by AZM (Figure 5A). However, overexpression of
PA3297 in wild type PA14 did not further increase the bacterial
FIGURE 5 | Expression of PA3297 in the presence of AZM. (A) Wild type
PA14 was grown to an OD600 of 0.3 in LB medium. The bacteria were grown
further in the absence or presence of 2, 5, or 10 µg/ml AZM. When the OD600
reached 2.0, total bacterial RNA was isolated and the mRNA levels of PA3297
were determined with real time PCR. ∗p < 0.05 compared to bacteria in the
absence of presence of 2 or 5 µg/ml AZM by student’s t-test. (B) PA14
harboring pMMB67EH or the ErmC over expressing plasmid
(pMMB67EH-ermC) was grown at 37◦Cin the absence of AZM. When the
OD600 reached 0.3, 1 mM IPTG was added to the medium. Meanwhile, no
AZM or AZM at the final concentration of 10 µg/ml was added to the medium.
At the OD600 of 2.0, total RNA was isolated and the mRNA levels of PA3297
were determined with real time PCR. The mRNA levels of lacI from the
plasmid were used as internal control. ∗p < 0.05 compared to
PA14/pMMB67EH by student’s t-test.
TABLE 4 | Bacterial susceptibilities to macrolides and lincosamides.
Strain MIC (µg/ml)a
ERY AZM LIN CLI
PA14/pMMB67EH 600 200 12800 12800
PA14/pMMB67-PA3297 600 200 12800 6400
PA14/pMMB67-ermC 2400 800 >12800 >12800
1PA3297/pMMB67EH 75 50 6400 3200
1PA3297/pMMB67-PA3297 300 200 12800 3200
1PA3297/pMMB67-ermC 2400 400 >12800 >12800
aERY, erythromycin; AZM, azithromycin; LIN, lincomycin; CLI, clindamycin.
tolerance to AZM (Table 4). We suspect that since the bacteria
at exponential growth phase are highly resistant to macrolides
and lincosamides, overexpression of PA3297 might not further
increase the resistance significantly in the MIC test. Another
possibility is that with the endogenous up regulation of PA3297,
additional expression of PA3297 might be redundant.
Köhler et al. (2007) previously demonstrated that ribosome
is the only target of AZM in bacteria. To test whether the
induction of PA3297 is caused by the interaction between AZM
and ribosome, we performed the ribosomal protection assay by
overexpressing ErmC, a 23S rRNA methylase that blocks the
binding of macrolide antibiotics to the NPET (Köhler et al.,
2007; Lawrence et al., 2008). In the presence of 10 µg/ml
AZM, the growth speed of the ErmC overexpressing strain
was similar with that of the wild type strain containing an
empty vector. However, overexpression of ErmC abolished
the induction of PA3297 by AZM (Figure 5B). In addition,
antibiotics in the other categories, including ciprofloxacin,
tobramycin, and carbenicillin did not affect the expression level of
PA3297 (Supplementary Figure S2). These results suggest that the
expression of PA3297 is regulated in response to AZM-mediated
ribosome stalling.
Ribosome Protection Rescues the
1PA3297 Mutant from AZM-Mediated
Hyperlethality
So far, we have demonstrated that the expression of PA3297
is induced by AZM and that mutation of PA3297 renders
P. aeruginosa hypersusceptible to AZM. These results suggest that
PA3297 might play a role in counteracting the detrimental effects
caused by the interaction between AZM and ribosome (Köhler
et al., 2007; Gödeke et al., 2013). Thus, ribosome protection
should be able to increase the tolerance of the 1PA3297 mutant
to AZM. Indeed, overexpression of ErmC increased both the
growth speed and the survival rate of the1PA3297 mutant when
treated with 10 or 40 µg/ml AZM (Supplementary Figure S3,
Figure 6). In addition, overexpression of ErmC increased the
MICs of both wild type PA14 and the 1PA3297 mutant to AZM,
erythromycin, lincomycin and clindamycin (Table 4). Mutation
of PA3297 did not increase the bacterial susceptibility to a variety
of other antibiotics (Supplementary Table S1). These results
suggest a specific role of PA3297 in responding to lincosamides
and macrolides.
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FIGURE 6 | Effects of Ribosome protection on the AZM mediated
killing of the 1PA3297 mutant. Wild type PA14 or the 1PA3297 mutant
harboring pMMB67EH or pMMB67EH-ermC was grown to an OD600 of 0.5
when 1 mM IPTG was added to the medium. When the OD600 reached 2.0,
the bacteria were treated without or with 10 or 40 µg/ml AZM for 20 h at
37◦C. The numbers of live bacteria were determined by serial dilution and
plating. ∗p < 0.05 compared to the 1PA3297 mutant harboring pMMB67EH
by student’s t-test.
Deficiency in PA3297 Compromises
rRNA Processing in the Presence of AZM
Studies in E. coli demonstrated that the DExD/H box play crucial
roles in rRNA processing (Iost et al., 2013; Linder and Fuller-Pace,
2013). Therefore, we suspected that the up regulated PA3297
might participate in rRNA maturation, which facilitates ribosome
biogenesis to compensate for AZM inactivated ribosome. The
rRNA coding region in the chromosome of P. aeruginosa
PA14 is shown in Supplementary Figure S4. To examine the
processing of the rRNA transcript, we designed real-time PCR
primers to analyze the total 23S and 5S rRNA levels as well
as primers across the 23S and 5S rRNA coding region to
analyze the level of unprocessed rRNA (Supplementary Figure
S4). In wild type PA14, AZM at the concentrations of 5 and
10 µg/ml reduced the 23S and 5S rRNA levels (Figures 7A,B),
and 10 µg/ml AZM slightly increased the unprocessed 23S-
5S rRNA level (Figure 7C). In the absence of AZM, the total
23S and 5S rRNA levels were higher in the 1PA3297 mutant
than those in the wild type strain (Figures 7A,B), whereas the
unprocessed 23S-5S levels were similar between the mutant and
wild type strain. Interestingly, treatment with 10 µg/ml AZM
resulted in a higher level of unprocessed 23S-5S rRNA in the
1PA3297 mutant (Figure 7C), although its total 23S and 5S
rRNA levels were lower than those in the wild type strain
(Figures 7A,B).
Next, we calculated the percentages of unprocessed 23S-5S
rRNA in wild type PA14 and the 1PA3297 mutant with or
without AZM treatment. Standard curves were generated to
determine the amplification efficiencies of the primer pairs for
the detection of total 23S, 5S and unprocessed 23S-5S rRNA
levels in real time PCR (Supplementary Figure S5). Considering
5S rRNA is more prone to be lost during RNA purification, we
calculated the ratio of unprocessed 23S-5S rRNA by dividing the
levels of 23S-5S rRNA by those of 23S rRNA calibrated with the
amplification efficiencies (Table 5). In the absence of AZM, the
FIGURE 7 | Effects of AZM on the processing of rRNA. PA14, the
1PA3297 mutant and the complemented strain were grown at 37◦C in the
absence of AZM. When the OD600 reached 0.3, AZM (0, 5, and 10 µg/ml)
was added. Total RNA was harvested when the OD600 reached 2.0. The
levels of total 23S (A), 5S (B), and unprocessed 23S-5S rRNA (C) were
determined by real time PCR. The mRNA levels of PA1769 were used as an
internal control. ∗p < 0.05 compared to PA14 by student’s t-test.
ratios of unprocessed 23S-5S rRNA were approximately 0.014 and
0.009% in wild type PA14 and the1PA3297 mutant, respectively.
It seems that, without PA3297, the processing of 23S-5S rRNA is
even more efficient. In the presence of 5 and 10 µg/ml AZM, the
ratios of unprocessed 23S-5S rRNA rose to approximately 0.05
and 0.09% in wild type PA14, respectively. However, the ratios
of unprocessed 23S-5S rRNA in the 1PA3297 mutant were 0.33
and 1.61%, which were approximately 5- and 18-fold higher than
those in PA14 under the same condition (Table 5).
Since, the growth speed of the 1PA3297 mutant in the
presence of 10 µg/ml AZM was similar as that of the wild
type PA14 in the presence of 40 µg/ml AZM (Supplementary
Figure S3), we compared the rRNAs levels of the two strains
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TABLE 5 | The ratio of unprocessed 23S-5S rRNA in total 23S rRNA (%).
Strain AZM (µg/ml)
0 5 10
PA14 0.014 0.051 0.089
1PA3297 0.009 0.335 1.608
The unprocessed 23S-5S rRNA ratios were calculated according to the equation:
Ratio = (1+e23S)Ct(23S)/(1+e23S-5S)Ct(23S-5S); e: Amplification efficiency. Ct: Cycles
when fluorescence intensity reaches detection threshold.
grown under the two conditions. The relative levels of 23S-5S
rRNA, total 5S and 23S rRNA in the 1PA3297 mutant were
150, 55, and 100% of those in the wild type PA14, respectively,
indicating a similar rRNA processing status with the two different
AZM concentrations. In combination, these results suggest that
PA3297 might contribute to rRNA processing in response to
AZM. And mutation of PA3297 might impair the biosynthesis
of ribosome under AZM treatment, which renders the bacterium
more susceptible to AZM.
DISCUSSION
By binding to 23S rRNA in the 50S subunit of bacterial
ribosome, AZM blocks polypeptide elongation and diminishes
the intracellular pools of aminoacyl-tRNAs (Tenson et al., 2003;
Gödeke et al., 2013; Wilson, 2014). And it has been demonstrated
that AZM reduces the expression of gacA and the small RNAs
rsmY and rsmZ, as well as quorum sensing genes (Kai et al.,
2009; Pérez-Martínez and Haas, 2011). And the stationary phase
killing by sub-MIC AZM was demonstrated to be correlated
with increased outer membrane permeability (Imamura et al.,
2005). Here, we found that mutation of PA3297 intensified the
AZM mediated inhibitory effects on pyocyanin production and
swarming motility of P. aeruginosa. In addition, the PA3297
mutant is more susceptible to oxidative stress in the presence
of AZM. During infection, host generated reactive oxygen
species (ROS) is an important bacterial killing mechanism.
Therefore, inhibition of PA3297 together with the treatment
with AZM, might render the bacteria more susceptible to host
killing.
The MIC of the 1PA3297 mutant is a quarter of that of the
wild type strain. Consistently, the growth speed of the 1PA3297
mutant in the presence of 10 µg/ml AZM was similar as that
of the wild type strain in the presence of 40 µg/ml AZM
(Supplementary Figure S3). However, in the stationary phase cell
killing assay, the survival rate of the 1PA3297 mutant treated
with 10 µg/ml AZM was approximately 20% of that of the wild
type strain treated with 40 µg/ml AZM (Figure 6). Therefore,
PA3297 might play a more important role in the survival of
stationary phase cells under AZM treatment.
Macrolides and lincosamides bind to the 50S of ribosome
and block the NPET (Tenson et al., 2003). In our experiments,
mutation in PA3297 did not alter the bacterial resistance to other
antibiotics, including those binding to 30S or other parts of 50S
ribosome. In addition, the expression of PA3297 was upregulated
by AZM, which was abolished by ribosome protection. Therefore,
PA3297 might specifically play a role in bacterial response to
macrolides and lincosamides.
PA3297 is also named HrpA, both in PAO1 and PA14 (Winsor
et al., 2016). According to the Profiles from GEO Expression
Database at NCBI, the expression level of PA3297 was higher
in biofilm than that in planktonic cells (Anderson et al., 2008).
Isolates from CF lungs displayed higher expression levels of
PA3297 levels than PAO1 (Son et al., 2007; Bielecki et al.,
2013). And artificial medium that mimics CF lung sputum
could increase the expression level of PA3297 slightly (Fung
et al., 2010). In addition, increase of PA3297 expression was
also observed in antibiotic-resistant small colony variants (Wei
et al., 2011). However, the expression level of PA3297 showed
a significant decrease in response to airway epithelia or low
oxygen conditions (Alvarez-Ortega and Harwood, 2007; Chugani
and Greenberg, 2007). These results indicate that the expression
of PA3297 is regulated in response to various environmental
stesses.
PA3297 is predicted to locate at the cytoplasmic membrane,
with a molecular weight of 149.8 kDa (Winsor et al., 2016). It
belongs to the DExD/H box helicase family. Members of this
family have been found to play crucial roles in RNA metabolism
and gene regulation (Linder and Jankowsky, 2011; Iost et al.,
2013; Kaberdin and Bläsi, 2013; Linder and Fuller-Pace, 2013;
Putnam and Jankowsky, 2013). According to NCBI protein blast,
there are 81 homologous proteins with identities of 78% or more
in other microorganisms. The homolog of PA3297 in Borrelia
burgdorferi was found to be required for mouse infectivity and
tick transmission and involved global gene regulation (Salman-
Dilgimen et al., 2011; Owttrim, 2013). Another homolog in
E. coli was found to be involved in fimbrial biogenesis (Koo
et al., 2004). The identities they shared with PA3297 are 34 and
49%, respectively. Both of them possess the conserved residues
in motif I, motif II, and motif III. Meanwhile, they are also
involved in RNA processing. In Listeria monocytogenes, it has
been reported that defect of a DExD-box RNA helicase, Lmo1722,
reduced the maturation of 23S RNA (Bareclev et al., 2014) at low
temperatures.
In E. coli, the primary transcript rRNA is cleaved by RNase III,
yielding precursors of the 16S rRNA (17S rRNA), 23S rRNA, and
5S rRNA (9S rRNA; Shajani et al., 2011). Mutation of RNase III
led to slower growth rate, reduction in cell viability and protein
synthesis rates in the presence of AZM (Silvers and Champney,
2005). In E. coli, under certain stress conditions, DEAD box
helicase may substitute for RhlB in the degradosome, such
as CsdA under cold shock conditions (Prud’homme-Généreux
et al., 2004). We found that mutation of PA3297 increased
the percentage of unprocessed 23S-5S rRNA in the presence of
AZM, which indicates that the cleaving function of RNase III
might be impaired under the stress caused by AZM. Therefore,
PA3297 might assist RNase III in rRNA processing in the
presence of AZM. In addition, although the growth speed and
rRNA processing in the 1PA3297 mutant treated with 10 µg/ml
AZM were similar to those in the wild type strain treated with
40 µg/ml AZM (Supplementary Figure S3), the survival rate of
the 1PA3297 mutant was lower than that of the wild type strain
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under those conditions. Thus, PA3297 might play other roles in
counteracting the effects of AZM.
Overall, mutation of PA3297 renders P. aeruginosa more
susceptible to AZM mediated inhibition on virulence factors
and killing effect. Therefore, targeting the regulatory pathway
or the function of PA3297 might further increase the beneficial
effects of AZM in the treatment of chronic P. aeruginosa
infections.
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